GEN Exclusives

More »

New Products

Whether you are searching for a DNA purification kit or outfitting a cGMP facility, GEN’s comprehensive new product database is your first and only stop. Conveniently categorized and searchable, the database covers the latest innovations from industry-leading suppliers.

Agilent Technologies

  • Page 1 of 1 (4 items) 1 

Gas Chromatography Column Connection

Agilent Technologies

Enhance column connections, prolong column life, and extend the inert flow path with leak-free GC column connections supplies. Users will see an improvement in GC flow-path integrity and experience longer periods of unattended operation. Laborat...

Liquid Chromatography Injection System

Agilent Technologies

The 1290 Infinity Multisampler, a liquid chromatography autosampler, provides newly optimized, scalable throughput capacity. Using shallow well-plate drawers, the 1290 Infinity Multisampler takes a maximum load of 16 microtiter plates and up to ...

Monoclonal Antibodies Separation Columns

Agilent Technologies

The AdvanceBio RP-mAb is a reversed-phase column optimized to separate monoclonal antibodies. The columns leverage Poroshell technology for fast, high-resolution analysis of intact mAbs. The column is 3.5 µm, 450Å superficial...

DNA Integrity Number for Tissue Samples

Agilent Technologies

A new feature has been added to the Genomic DNA ScreenTape assay, the DNA Integrity Number (DIN), for assessing the integrity of genomic DNA. The feature is designed to ensure the quality of genomics experiments, especially next-generation seque...

  • Page 1 of 1 (4 items) 1 

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Moral Calculations May Shift Biobank Balances

How should consent terms reconcile donors’ moral concerns with biobanks’ research goals?